Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery

PharmacoEconomics

Volumn 19, Issue 5 II, 2001, Pages 589-597

  Levin, L A ^a   Bergqvist, D ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DESULFATOHIRUDIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT HIRUDIN;

AGED; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DEEP VEIN THROMBOSIS; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; SWEDEN; TOTAL HIP PROSTHESIS;

EID: 0035009732     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119050-00012     Document Type: Article

References (24)

1. Consensus statement. Prevention of venous thromboembolism
2. Risk of and prophylaxis for venous thromboembolism in hospital patients
3. Prevention of venous thromboembolism
4. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: An meta-analysis
5. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement
6. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
7. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc®) with that of unfractionated heparin in patients having a total hip replacement
8. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement
9. Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hipreplacementsurgery
10. Prevention of venous thromboembolism after general surgery. Cost-effectiveness analysis of alternative approaches to prophylaxis
11. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery
12. Two strategies for prophylaxis of fatal postoperative pulmonary embolism. Cost-effectiveness analysis
13. The economics of general thromboembolic prophylaxis
14. Cost-effectiveness of prophylaxis in total hip replacement
15. Cost-effectiveness of venous thromboembolism prophylaxis in surgery
16. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after hip replacement
17. Long-term outcomes of deep-vein thrombosis
18. Cost of long-term complications of deep venous thrombosis of the lower extremities: An analysis of a defined patient population in Sweden
19. Five-hundred life-saving interventions and their cost-effectiveness
20. Cost-effectiveness of cholesterol lowering. Results from the scandinavian simvastatin survival study (4S)
21. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison